Bicara Therapeutics (BCAX) Equity Ratio (2023 - 2026)

Bicara Therapeutics posted quarterly Equity Ratio of 0.93 for Q1 2026, down 3.29% year-on-year from 0.96 in Q1 2025, and little changed on a QoQ basis from 0.93 in Q4 2025.

Bicara Therapeutics (BCAX) has 4 years of Equity Ratio data on file, last reported at 0.93 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio fell 3.29% year-over-year to 0.93; the trailing twelve-month figure through Mar 2026 stood at 0.93 (down 3.29% YoY), and the FY2025 full-year result was 0.93, down 3.42% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.93, roughly flat from 0.93 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.97 in Q3 2024 and bottomed at 0.64 in Q4 2023.
  • The 4-year median for Equity Ratio is 0.95 (2025), against an average of 0.75.
  • The widest annual swing landed in 2024, when Equity Ratio soared 251.69%; it then fell 3.42% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.64 in 2023, then jumped by 251.69% to 0.96 in 2024, then decreased by 3.42% to 0.93 in 2025, then retreated by 0.33% to 0.93 in 2026.
  • The last three Equity Ratio figures came in at 0.93 (Q1 2026), 0.93 (Q4 2025), and 0.95 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 0.04
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.42
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.73
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.77
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.21
10 Bicara Therapeutics 1.25 Bn 1.25 Bn - 0.93

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.93
Dec 31, 2025 0.93
Sep 30, 2025 0.95
Jun 30, 2025 0.96
Mar 31, 2025 0.96
Dec 31, 2024 0.96
Sep 30, 2024 0.97
Dec 31, 2023 -0.64